Law.com Subscribers SAVE 30%
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Drug & Device News
Trade Secrets vs. the Public's Right to Know
As part of its efforts to combat rampant drug abuse, the City of Chicago is suing several opioid-drug manufacturers, claiming that they have engaged in “a scheme to misinform the health care community and consumers about the risks, benefits and superiority of the opium-like painkillers” they manufacture. The City agreed to redaction of part of the complaint and some of the pre-suit investigative materials, at the drug manufacturers' request, the manufacturers asserting that these things included confidential company information. But three news outlets ' The Los Angeles Times, USA Today and The Chicago Tribune ' moved in mid-July to intervene in the lawsuit to unseal the redacted materials. They claim that their First Amendment and common law rights to access to judicial proceedings are being limited by the redactions, and that the public has a right to know what is happening in the case. Named in the lawsuit are pharmaceuticals companies Actavis PLC, Cephalon Inc., Endo Health Solutions Inc., Janssen Pharmaceuticals Inc., Johnson & Johnson, the Purdue Frederick Company Inc., Purdue Pharma Inc., Purdue Pharma L.P., and Teva Pharmaceutical Industries, Ltd.
This premium content is locked for LJN Newsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Corporate Enforcement Policy: One Year Later
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Use of Deferred Prosecution Agreements In White Collar Investigations
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
The DOJ's New Parameters for Evaluating Corporate Compliance Programs
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
CLE Shouldn't Be the Only Mandatory Training for Attorneys
Each stage of an attorney's career offers opportunities for a curriculum that addresses both the individual's and the firm's need to drive success.
Discovery of Claim Construction and Infringement Analysis May be Compelled Prior to a Markman Hearing
A defendant in a patent infringement suit may, during discovery and prior to a <i>Markman</i> hearing, compel the plaintiff to produce claim charts, claim constructions, and element-by-element infringement analyses.